340 related articles for article (PubMed ID: 34274492)
21. Homologous and Heterologous Covid-19 Booster Vaccinations.
Atmar RL; Lyke KE; Deming ME; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Posavad CM; Archer JI; Crandon S; Nayak SU; Szydlo D; Zemanek JA; Dominguez Islas CP; Brown ER; Suthar MS; McElrath MJ; McDermott AB; O'Connell SE; Montefiori DC; Eaton A; Neuzil KM; Stephens DS; Roberts PC; Beigel JH;
N Engl J Med; 2022 Mar; 386(11):1046-1057. PubMed ID: 35081293
[TBL] [Abstract][Full Text] [Related]
22. Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): A cross-sectional study.
Massoud F; Ahmad SF; Hassan AM; Alexander KJ; Al-Hashel J; Arabi M
Seizure; 2021 Nov; 92():2-9. PubMed ID: 34391030
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.
Piñana JL; López-Corral L; Martino R; Montoro J; Vazquez L; Pérez A; Martin-Martin G; Facal-Malvar A; Ferrer E; Pascual MJ; Sanz-Linares G; Gago B; Sanchez-Salinas A; Villalon L; Conesa-Garcia V; Olave MT; López-Jimenez J; Marcos-Corrales S; García-Blázquez M; Garcia-Gutiérrez V; Hernández-Rivas JÁ; Saus A; Espigado I; Alonso C; Hernani R; Solano C; Ferrer-Lores B; Guerreiro M; Ruiz-García M; Muñoz-Bellido JL; Navarro D; Cedillo A; Sureda A;
Am J Hematol; 2022 Jan; 97(1):30-42. PubMed ID: 34695229
[TBL] [Abstract][Full Text] [Related]
24. Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study.
La Rosa C; Chiuppesi F; Park Y; Zhou Q; Yang D; Gendzekhadze K; Ly M; Li J; Kaltcheva T; Ortega Francisco S; Gutierrez MA; Ali H; Otoukesh S; Amanam I; Salhotra A; Pullarkat VA; Aldoss I; Rosenzweig M; Aribi AM; Stein AS; Marcucci G; Dadwal SS; Nakamura R; Forman SJ; Al Malki MM; Diamond DJ
Front Immunol; 2023; 14():1114131. PubMed ID: 36936918
[TBL] [Abstract][Full Text] [Related]
25. Serological findings following the second and third SARS-CoV-2 vaccines in lung transplant recipients.
Bárczi E; Varga V; Nagy A; Eszes N; Jáky-Kováts Z; Müller V; Bohács A
Immun Inflamm Dis; 2022 Aug; 10(8):e646. PubMed ID: 35894705
[TBL] [Abstract][Full Text] [Related]
26. Predictors of impaired antibody response after SARS-CoV-2 mRNA vaccination in hematopoietic cell transplant recipients: A Japanese multicenter observational study.
Mori Y; Uchida N; Harada T; Katayama Y; Wake A; Iwasaki H; Eto T; Morishige S; Fujisaki T; Ito Y; Kamimura T; Takahashi T; Imamura Y; Tanimoto K; Ishitsuka K; Sugita J; Kawano N; Tanimoto K; Yoshimoto G; Choi I; Hidaka T; Ogawa R; Takamatsu Y; Miyamoto T; Akashi K; Nagafuji K
Am J Hematol; 2023 Jan; 98(1):102-111. PubMed ID: 36260658
[TBL] [Abstract][Full Text] [Related]
27. mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients.
Albiol N; Aso O; Gómez-Pérez L; Triquell M; Roch N; Lázaro E; Esquirol A; González I; López-Contreras J; Sierra J; Martino R; García-Cadenas I
Support Care Cancer; 2022 Dec; 30(12):9687-9690. PubMed ID: 36169731
[TBL] [Abstract][Full Text] [Related]
28. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
[TBL] [Abstract][Full Text] [Related]
30. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.
Hanson KE; Goddard K; Lewis N; Fireman B; Myers TR; Bakshi N; Weintraub E; Donahue JG; Nelson JC; Xu S; Glanz JM; Williams JTB; Alpern JD; Klein NP
JAMA Netw Open; 2022 Apr; 5(4):e228879. PubMed ID: 35471572
[TBL] [Abstract][Full Text] [Related]
31. Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation.
Bankova AK; Pasin C; Huang A; Cicin-Sain C; Epp S; Audige A; Mueller NJ; Nilsson J; Vilinovszki O; Nair G; Wolfensberger N; Hockl P; Schanz U; Trkola A; Kouyos R; Hasse B; Zinkernagel AS; Manz MG; Abela IA; Müller AMS
Br J Haematol; 2023 Apr; 201(1):58-63. PubMed ID: 36382698
[TBL] [Abstract][Full Text] [Related]
32. Humoral and cellular immune responses to Pfizer-BioNTech BNT162b2 SARS-CoV-2 vaccine in adolescents with liver transplantation: Single center experience.
Sánchez-Zapardiel E; Alós M; Nozal P; González-Muñoz M; Frauca-Remacha E; Gavilán LB; Quiles MJ; Hierro L; López-Granados E
Front Immunol; 2022; 13():1049188. PubMed ID: 36505469
[TBL] [Abstract][Full Text] [Related]
33. An observational study of adverse drug reactions to COVID-19 vaccines reported to the New Mexico poison center hotline.
Tadfor Y; Nguyen-Hua N; Bennett H; Bos AJ; Smolinske SC
Clin Toxicol (Phila); 2023 Jan; 61(1):77-83. PubMed ID: 36458888
[TBL] [Abstract][Full Text] [Related]
34. Is a third SARS-CoV-2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients?
Spyridonidis A
Br J Haematol; 2023 Apr; 201(1):9-10. PubMed ID: 36477621
[TBL] [Abstract][Full Text] [Related]
35. Serologic Responses following a Single Dose of SARS-Cov-2 Vaccination in Allogeneic Stem Cell Transplantation Recipients.
Easdale S; Shea R; Ellis L; Bazin J; Davis K; Dallas F; Thistlethwayte E; Ethell M; Potter M; Arias C; Anthias C; Nicholson E
Transplant Cell Ther; 2021 Oct; 27(10):880.e1-880.e4. PubMed ID: 34293520
[TBL] [Abstract][Full Text] [Related]
36. Development of donor specific antibodies after SARS-CoV-2 vaccination in kidney and heart transplant recipients.
McCune TR; Bray RA; Baran DA; Toepp AJ; Forte SJ; Gilgannon LT; Williams T; Chen S; Sadr H; Gebel HM; Herre JM
Transpl Immunol; 2022 Dec; 75():101722. PubMed ID: 36152939
[TBL] [Abstract][Full Text] [Related]
37. Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US.
Li X; Burn E; Duarte-Salles T; Yin C; Reich C; Delmestri A; Verhamme K; Rijnbeek P; Suchard MA; Li K; Mosseveld M; John LH; Mayer MA; Ramirez-Anguita JM; Cohet C; Strauss V; Prieto-Alhambra D
BMJ; 2022 Oct; 379():e071594. PubMed ID: 36288813
[TBL] [Abstract][Full Text] [Related]
38. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
Self WH; Tenforde MW; Rhoads JP; Gaglani M; Ginde AA; Douin DJ; Olson SM; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Mills L; Lester SN; Stumpf MM; Naioti EA; Kobayashi M; Verani JR; Thornburg NJ; Patel MM;
MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1337-1343. PubMed ID: 34555004
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients.
Shem-Tov N; Yerushalmi R; Danylesko I; Litachevsky V; Levy I; Olmer L; Lusitg Y; Avigdor A; Nagler A; Shimoni A; Rahav G
Br J Haematol; 2022 Feb; 196(4):884-891. PubMed ID: 34713441
[TBL] [Abstract][Full Text] [Related]
40. Impact of a third dose of anti-SARS-CoV-2 vaccine in hematopoietic cell transplant recipients: A Japanese multicenter observational study.
Mori Y; Uchida N; Wake A; Miyawaki K; Eto T; Nakamura T; Iwasaki H; Ito Y; Tanimoto K; Katayama Y; Imamura Y; Takahashi T; Fujisaki T; Kamimura T; Choi I; Ishitsuka K; Yoshimoto G; Ogawa R; Sugita J; Takamatsu Y; Tanimoto K; Hidaka T; Miyamoto T; Akashi K; Nagafuji K
Vaccine; 2023 Nov; 41(47):6899-6903. PubMed ID: 37866994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
